[Federal Register Volume 81, Number 33 (Friday, February 19, 2016)]
[Notices]
[Pages 8508-8509]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-03469]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2016-N-0567]


Pediatric Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; request for comments.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Pediatric Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the Agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on April 12, 2016, from 8 
a.m. to 5:30 p.m.

ADDRESSES: FDA is establishing a public docket [Docket No. FDA-2016-N-
0567] to receive input on pediatric-focused safety reviews and 
appropriate pediatric development plans for prescription opioid drugs. 
Comments about the upcoming September advisory committee meeting should 
not be submitted to the docket number listed at the top of this Federal 
Register notice [Docket No. FDA-2016-N-0567], which is to provide an 
opportunity for the public to provide input concerning the products 
before the Committee on April 12, 2016.
    Location: Double Tree by Hilton Hotel, 8727 Colesville Rd., Silver 
Spring, MD 20910, 301-589-5200. Answers to commonly asked questions 
including information regarding special accommodations due to a 
disability, visitor parking, and transportation may be accessed at: 
http://doubletree3.hilton.com/en/hotels/maryland/doubletree-by-hilton-hotel-washington-dc-silver-spring-DCASSDT/index.html.
    Contact Person: Marieann Brill, Office of the Commissioner, Food 
and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 5154, 
Silver Spring, MD 20993, 240-402-3838, email: 
[email protected], or FDA Advisory Committee Information Line, 
1-800-741-8138 (301-443-0572 in the Washington, DC area). A notice in 
the Federal Register about last minute modifications that impact a 
previously announced advisory committee meeting cannot always be 
published quickly enough to provide timely notice. Therefore, you 
should always check the Agency's Web site at http://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate 
advisory committee meeting link, or call the advisory committee 
information line to learn about possible modifications before coming to 
the meeting.
    Agenda: On April 12, 2016, the Pediatric Advisory Committee (PAC) 
will meet to discuss pediatric-focused safety reviews, as mandated by 
the Best Pharmaceuticals for Children Act (Pub. L. 107-109) and the 
Pediatric Research Equity Act (Pub. L. 108-155). See the list of the 
products in this document to be discussed.
    In addition, FDA will be providing information on a proposed public 
advisory committee meeting for September 15 and 16, 2016, on 
appropriate pediatric development plans for prescription opioid drugs. 
Prior to the safety reviews and the open public hearing (see later in 
this section for further information), FDA will present, from 
approximately 8:30 to 9:30 a.m., a framework of current plans for a 2-
day joint meeting of the PAC, the Anesthetic and Analgesic Drug 
Products Advisory Committee, and the Drug Safety and Risk Management 
Advisory Committees.
    Elsewhere in this issue of the Federal Register, FDA is publishing 
an announcement of this advisory committee meeting to be held on 
September 15 and 16, 2016, on the FDA White Oak Campus, 10903 New 
Hampshire Ave., Building 31 Conference Center, the Great Room (rm. 
1503), Silver Spring, MD 20993-0002. Following the presentation on the 
proposed framework for the September meeting, there will be an hour of 
open public hearing from 9:30 a.m. to 10:30 a.m. to provide an 
opportunity for the public to provide input concerning the topics 
before the PAC, including the use of opioids for control of severe pain 
in the pediatric population. To assist with the planning of this 
advisory committee meeting, FDA is establishing a public docket [Docket 
No. FDA-2016-N-0584] to receive input on appropriate pediatric 
development plans for prescription opioid drugs. The docket will remain 
open following the September advisory committee meeting. Comments about 
the upcoming September advisory committee meeting should not be 
submitted to the docket number listed at the top of this Federal 
Register notice [Docket No. FDA-2016-N-0567]. Please also see the 
ADDRESSES section of this notice for further docket information.
    The pediatric-focused safety reviews for the Centers will then 
occur. The PAC will meet to discuss the following products (listed by 
FDA Center):

 Center for Biologics Evaluation and Research (CBER):
    [cir] FLULAVAL QUADRIVALENT (influenza virus vaccine)
    [cir] FLULAVAL TRIVALENT (influenza virus vaccine)
    [cir] FLUZONE QUADRIVALENT (influenza virus vaccine)
 Center for Drug Evaluation and Research (CDER):
    [cir] ACIPHEX SPRINKLES (rabeprazole sodium)
    [cir] SKYLA (levonorgestrel-releasing intrauterine system)
    [cir] MYCAMINE (micafungin sodium)
    [cir] NOXAFIL (posaconazole)
    [cir] PRECEDEX (dexmedetomidine hydrocholoride)
    [cir] SABRIL (vigabatrim)
    [cir] SEROQUEL (quetiapine fumarate) and SEROQUEL XR (quetiapine 
fumarate extended-release)

[[Page 8509]]

    [cir] SKYLA (levonorgestrel-releasing intrauterine system)
    [cir] SYMBAX (fluoxetine hydrocholoride and olanzapine)
    [cir] VYVANSE CAPSULES (lisdexamfetamine dimesylate)
    [cir] XELODA (capecitabine)
 Center for Devices and Radiological Health (CDRH):
    [cir] IMPELLA RP SYSTEM (humanitarian use device (HUD))
    [cir] LIPSORBER LA-15 SYSTEM (HUD)
    [cir] MEDTRONIC ACTIVA DYSTONIA THERAPY (HUD)

    In addition to the agenda items, the PAC will remain in public 
session over the lunch hour on April 12, 2016, to hear a presentation 
and provide feedback on an FDA proposal for a risk-based approach to 
the pediatric-focused safety reviews mandated by the Best 
Pharmaceuticals for Children Act and the Pediatric Research Equity Act. 
The working lunch currently is scheduled between approximately 12:30 
p.m. and 1:15 p.m.
    FDA intends to make background material available to the public no 
later than 2 business days before the meeting. If FDA is unable to post 
the background material on its Web site prior to the meeting, the 
background material will be made publicly available at the location of 
the advisory committee meeting, and the background material will be 
posted on FDA's Web site after the meeting. Background material is 
available at http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting 
link.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person on or before 
April 5, 2016. Oral presentations from the public will be scheduled 
between approximately 9:30 a.m. and 10:30 a.m. Those individuals 
interested in making formal oral presentations should notify the 
contact person and submit a brief statement of the general nature of 
the evidence or arguments they wish to present, the names and addresses 
of proposed participants, and an indication of the approximate time 
requested to make their presentation on or before March 28, 2016. Time 
allotted for each presentation may be limited. If the number of 
registrants requesting to speak is greater than can be reasonably 
accommodated during the scheduled open public hearing session, FDA may 
conduct a lottery to determine the speakers for the scheduled open 
public hearing session. The contact person will notify interested 
persons regarding their request to speak by March 29, 2016.
    Persons attending FDA's advisory committee meetings are advised 
that the Agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
disabilities. If you require accommodations due to a disability, please 
contact Marieann Brill at least 7 days in advance of the meeting.
    FDA is committed to the orderly conduct of its advisory committee 
meetings. Please visit our Web site at http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures 
on public conduct during advisory committee meetings.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: February 16, 2016.
Jill Hartzler Warner,
Associate Commissioner for Special Medical Programs.
[FR Doc. 2016-03469 Filed 2-18-16; 8:45 am]
 BILLING CODE 4164-01-P